Join this collaborative community of healthcare professionals dedicated to advancing the quality of care for women. This group will provide a platform for researchers and practitioners to exchange ideas, share knowledge, and stay informed on the latest best practices in women’s health. Emphasis will be placed on integrating cutting-edge scientific advancements with well-established, evidence-based approaches.
Upcoming Webinar: Beyond the Black Box: Practical Cardiovascular Counseling for Menopausal Hormone Therapy in 2026
Date: February 20, 2026 Time: 5:00 PM ET
Moderator:
Susan Tibuni-Sanders MD, Clinical Endocrinologist, Kaiser Permanente San Francisco
Speakers:
Cynthia Stuenkel MD, Clinical Professor of Medicine at the University of California, San Diego, School of Medicine
Emily Lau MD, MPH, Cardiologist and Investigator at Massachusetts General Hospital, Assistant Professor of Medicine at Harvard Medical School
Description:
Join us for a comprehensive 60-minute webinar featuring two leading experts as they examine the current evidence on hormone therapy (HT) and its role beyond vasomotor symptom management. Dr. Cynthia Stuenkel, endocrinologist at UC San Diego, and Dr. Emily Lau, cardiologist at Massachusetts General Hospital, will provide an evidence-based review of HT's risks and benefits, with particular focus on cardiovascular disease prevention, cognitive health, and bone protection.
As clinical guidelines continue to evolve and new indications are considered clinicians face the challenge of counseling patients using accurate, up-to-date data. This session will address what the evidence actually shows (and doesn't show) regarding HT use for coronary artery disease prevention, cognitive decline, and skeletal health, helping providers navigate these discussions with confidence.
This interdisciplinary presentation brings together endocrine and cardiovascular perspectives to equip healthcare providers with the tools needed for comprehensive, personalized HT counseling in contemporary practice.
Learning Objectives:
Integrate updated clinical guidelines into practice by summarizing the transition from the retired 2015 Endocrine Society CPG to the Endocrine Society–endorsed 2025 European Society of Endocrinology menopause/perimenopause guideline and describing the practical implications for cardiovascular counseling.
Translate-2025 FDA labeling changes into patient counseling by explaining what the boxed-warning revisions do—and do not do—mean for cardiovascular risk/benefit discussions and shared decision-making about MHT.
Please note: you must be a member of the SIG to view these webinar recordings.
Women's Health SIG Past Webinars
Bone Health During the Perimenopausal Transition
Date: December 2, 2025
Moderators:
Susan Tibuni-Sanders, MD, Kaiser Permanente, San Francisco, Chair of Women's Health SIG
Muriel Babey, MD, Assistant Professor of Medicine, Adjunct, University of California, San Francisco, Co-Chair of Bone and Mineral SIG
Speakers:
Maria Schuller Almeida, PhD, Professor, Departments of Internal Medicine and Orthopedic Surgery, Associate Director, Center for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences
Amanda L Clark, MD, MCR, MSCP, Professor Emeritam, Urogynecology and Reconstructive Pelvic Surgery, Obstetrics and Gynecology, Oregon Health & Science University
Mark Bolland, MD, Associate Professor, Faculty of Medical and Health Sciences, Medicine, University of Auckland, New Zealand
Description:
This webinar will examine bone health during the perimenopausal transition, a critical window of accelerated bone loss and skeletal adaptation. Presentations will review the hormonal and cellular mechanisms underlying perimenopausal bone loss, clinical approaches to assessment and prevention, and recent evidence from trials evaluating zoledronic acid for bone preservation.
Each presentation will last approximately 25 minutes, followed by a 5-minute question-and-answer session.
Learning Objectives:
Upon completion of this activity, participants will be able to:
Examine the basic and translational mechanisms driving bone loss during the perimenopausal transition.
Discuss clinical strategies for assessing, monitoring, and maintaining bone health during this period.
Understand the design and outcomes of the 5-yearly zoledronic acid trial and its implications for bone preservation.
Join this collaborative community of healthcare professionals dedicated to advancing the quality of care for women. This group will provide a platform for researchers and practitioners to exchange ideas, share knowledge, and stay informed on the latest best practices in women’s health. Emphasis will be placed on integrating cutting-edge scientific advancements with well-established, evidence-based approaches.
